NCT04182672View on ClinicalTrials.gov

Study to Assess the Safety and Efficacy of FX006 Administered to Patients With Greater Trochanteric Bursitis

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

August 12, 2020

Primary Completion Date

December 14, 2022

Study Completion Date

December 14, 2022

Conditions
Trochanteric Bursitis
Interventions
DRUG

FX006

Subjects will be injected with the 5mL of FX006. This injection may be followed with up to 3mL of ropivacaine (depending on the capacity of the bursa), under ultrasound guidance.

Trial Locations (1)

77030

The University of Texas Health Science Center at Houston, Houston

Sponsors
All Listed Sponsors
collaborator

Pacira Pharmaceuticals, Inc

INDUSTRY

lead

The University of Texas Health Science Center, Houston

OTHER